Lecture Title: Pharmacokinetics and Pharmacodynamics of Bufadienolides Delivered by Oral emulsion, Lipid Microspheres, Nano Lipid Carriers and Lipid-albumin Nanoparticles


Xing Tang


Prof. Xing Tang received his B.S. degree in pharmacy from Xi’an Medical College (1987), and M.S. degree in pharmaceutics from Shenyang Pharmaceutical College (1990). Since then he has been working as a faculty staff in Shenyang Pharmaceutical University. In 2000, he received his Ph.D. degree from Shenyang Pharmaceutical University. He has published over 150 papers with an H index of 26. He received 49 authorization of invention patent, including one PCT patent and 32 authorization as first inventor; received 11 new drug development certificates, including the one for “theophylline salbutamol sustained release tablets”; obtained 25 approval documents for new drug clinical study, including "docetaxel lipid microspheres injection"; hosted 69 enterprise-oriented technical services and 27 cooperative development projects, achieved a total scientific research fund of 31.75 million RMB. At present, the main research interests are as follows: targeted drug delivery system and nano-formulation development; sustained and controlled drug delivery system; pretreatment of insoluble drugs and new dosage form and new technology of Chinese Medicine.

Address:1 Beierjie,Zhongguancun, Beijing
P.C.:100190
Tel:+86 010 62647647
Fax:+86 010 82629146
E-mail:

formula9@ipe.ac.cn

Copyright © 1996-2012 Chinese Society of Particuology  All rights reserved  

Xing Tang

发布时间:2017-07-31

Lecture Title: Pharmacokinetics and Pharmacodynamics of Bufadienolides Delivered by Oral emulsion, Lipid Microspheres, Nano Lipid Carriers and Lipid-albumin Nanoparticles


Xing Tang


Prof. Xing Tang received his B.S. degree in pharmacy from Xi’an Medical College (1987), and M.S. degree in pharmaceutics from Shenyang Pharmaceutical College (1990). Since then he has been working as a faculty staff in Shenyang Pharmaceutical University. In 2000, he received his Ph.D. degree from Shenyang Pharmaceutical University. He has published over 150 papers with an H index of 26. He received 49 authorization of invention patent, including one PCT patent and 32 authorization as first inventor; received 11 new drug development certificates, including the one for “theophylline salbutamol sustained release tablets”; obtained 25 approval documents for new drug clinical study, including "docetaxel lipid microspheres injection"; hosted 69 enterprise-oriented technical services and 27 cooperative development projects, achieved a total scientific research fund of 31.75 million RMB. At present, the main research interests are as follows: targeted drug delivery system and nano-formulation development; sustained and controlled drug delivery system; pretreatment of insoluble drugs and new dosage form and new technology of Chinese Medicine.